Tumor Suppressor Candidate 3 As a Novel Predictor for Lymph Node Metastasis in Lung Cancer Patients

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Jan 21

PMID 28105217

Citations 6

Authors

Xinshuang Yu

Kaixian Zhang

Fengjun Liu

Jiandong Zhang

Chunjuan Zhai

Lili Cao

Xingye Song

Yao Wang

Baosheng Li

Hongjun Sun

Juan Du

Affiliations

Soon will be listed here.

Abstract

Tumor suppressor candidate 3 (TUSC3) was recently identified as a potential tumor suppressor gene in several cancer types. However, no data are currently available regarding the expression of TUSC3 in lung cancer. The present study investigated the expression of TUSC3 in patients with lung cancer and determined its association with the clinicopathological parameters of the disease. Cytoplasmic TUSC3 expression was evaluated by immunohistochemistry on tissue microarray slides, which included 35 small cell lung cancer (SCLC) specimens, 80 squamous cell lung cancer specimens (SCC), 80 adenocarcinoma lung cancer (ADC) specimens and 37 normal lung tissue specimens. Analysis showed significantly reduced TUSC3 expression in the SCLC patients, but not in the ADC and SCC patients, as compared with the normal controls. Additionally, TUSC3 expression in the patients with a degree of differentiation of 1-2 (well-moderately differentiated) was significantly higher than that in patients with a differentiation degree of 3-4 (poorly differentiated-undifferentiated). Further analysis showed that TUSC3 expression levels were negatively correlated with the degree of differentiation in the ADC and SCC patients. Notably, a marked decrease in TUSC3 expression was identified in the patients who were lymph node metastasis-positive (LNM) compared with patients who were LNM. Further analysis showed that significant differences in TUSC3 expression were identified among the different N stages (LNM status) in the SCLC, ADC and SCC patients. Correlation analysis also identified a negative correlation between TUSC3 expression and LNM in all three pathological types of lung cancer tested. Overall, these results indicated that a reduction in TUSC3 may be associated with a poorly-differentiated grade of lung cancer. Importantly, TUSC3 expression may be a useful predictor of LNM in lung cancer patients. A combined analysis of TUSC3 expression and the clinical variables will aid in predicting the incidence of LNM.

Citing Articles

MiR-320d Inhibits Progression of EGFR-Positive Colorectal Cancer by Targeting TUSC3.

Yufeng Z, Ming Q, Dandan W Front Genet. 2021; 12:738559.

PMID: 34733314 PMC: 8558375. DOI: 10.3389/fgene.2021.738559.

Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3.

Kong L, Sun Y, Chen M, Dai Y, Liu Z Exp Ther Med. 2020; 20(5):9.

PMID: 32934674 PMC: 7471862. DOI: 10.3892/etm.2020.9137.

miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.

Jeon Y, Kim T, Park D, Nuovo G, Rhee S, Joshi P Nat Commun. 2018; 9(1):5110.

PMID: 30504895 PMC: 6269493. DOI: 10.1038/s41467-018-07561-8.

Tumor suppressor candidate 3: A novel grading tool and predictor of clinical malignancy in human gliomas.

Yuan J, Yu X, Wang A, Li Y, Liu F, Wang Y Oncol Lett. 2018; 15(4):5655-5661.

PMID: 29556302 PMC: 5844021. DOI: 10.3892/ol.2018.8082.

Low levels of tumor suppressor candidate 3 predict poor prognosis of patients with hepatocellular carcinoma.

Sheng X, Xing S, Wang R, Chen K, Jia W Onco Targets Ther. 2018; 11:909-917.

PMID: 29503566 PMC: 5825997. DOI: 10.2147/OTT.S153381.

References

Horak P, Tomasich E, Vanhara P, Kratochvilova K, Anees M, Marhold M . TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo. Sci Rep. 2014; 4:3739. PMC: 3894551. DOI: 10.1038/srep03739. View

Ettinger D, Akerley W, Borghaei H, Chang A, Cheney R, Chirieac L . Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013; 11(6):645-53. DOI: 10.6004/jnccn.2013.0084. View

Herbst R, Heymach J, Lippman S . Lung cancer. N Engl J Med. 2008; 359(13):1367-80. PMC: 10662965. DOI: 10.1056/NEJMra0802714. View

MacGrogan D, Levy A, Bova G, Isaacs W, Bookstein R . Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics. 1996; 35(1):55-65. DOI: 10.1006/geno.1996.0322. View

Loddo S, Parisi V, Doccini V, Filippi T, Bernardini L, Brovedani P . Homozygous deletion in TUSC3 causing syndromic intellectual disability: a new patient. Am J Med Genet A. 2013; 161A(8):2084-7. DOI: 10.1002/ajmg.a.36028. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

Khalid A, Asano A, Hosaka Y, Takeuchi T, Yamano Y . Tumor suppressor candidate TUSC3 expression during rat testis maturation. Biosci Biotechnol Biochem. 2013; 77(10):2019-24. DOI: 10.1271/bbb.130327. View

Chute J, Chen T, Feigal E, Simon R, Johnson B . Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 1999; 17(6):1794-801. DOI: 10.1200/JCO.1999.17.6.1794. View

Guervos M, Alvarez Marcos C, Hermsen M, Sampedro Nuno A, Suarez C, Llorente J . Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas. Cell Oncol. 2007; 29(4):327-34. PMC: 4618212. DOI: 10.1155/2007/635962. View

10.

Mohorko E, Owen R, Malojcic G, Brozzo M, Aebi M, Glockshuber R . Structural basis of substrate specificity of human oligosaccharyl transferase subunit N33/Tusc3 and its role in regulating protein N-glycosylation. Structure. 2014; 22(4):590-601. DOI: 10.1016/j.str.2014.02.013. View

11.

Bova G, MacGrogan D, Levy A, Pin S, Bookstein R, Isaacs W . Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996; 35(1):46-54. DOI: 10.1006/geno.1996.0321. View

12.

Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G . Small cell lung cancer. Ann Oncol. 2006; 17 Suppl 2:ii5-10. DOI: 10.1093/annonc/mdj910. View

13.

Garshasbi M, Kahrizi K, Hosseini M, Vahid L, Falah M, Hemmati S . A novel nonsense mutation in TUSC3 is responsible for non-syndromic autosomal recessive mental retardation in a consanguineous Iranian family. Am J Med Genet A. 2011; 155A(8):1976-80. DOI: 10.1002/ajmg.a.34077. View

14.

Levy A, Dang U, Bookstein R . High-density screen of human tumor cell lines for homozygous deletions of loci on chromosome arm 8p. Genes Chromosomes Cancer. 1999; 24(1):42-7. DOI: 10.1002/(sici)1098-2264(199901)24:1<42::aid-gcc6>3.0.co;2-f. View

15.

Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus V . Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer. 2005; 104(11):2417-29. DOI: 10.1002/cncr.21538. View

16.

Aberle D, Berg C, Black W, Church T, Fagerstrom R, Galen B . The National Lung Screening Trial: overview and study design. Radiology. 2010; 258(1):243-53. PMC: 3009383. DOI: 10.1148/radiol.10091808. View

17.

Garshasbi M, Hadavi V, Habibi H, Kahrizi K, Kariminejad R, Behjati F . A defect in the TUSC3 gene is associated with autosomal recessive mental retardation. Am J Hum Genet. 2008; 82(5):1158-64. PMC: 2651624. DOI: 10.1016/j.ajhg.2008.03.018. View